Discovery May Lead to a Treatment to Slow Parkinson's Disease
Interaction between a mutant gene and alpha synuclein leads to hallmark Parkinson’s pathologies
In this study, researchers were able to see that LRRK2, a mutant kinase enzyme that is the most common genetic cause for Parkinson’s disease, can cause the buildup of inclusions in neurons. These inclusions are one of the main pathologies seen in patients with Parkinson’s disease. New drugs that are currently being developed for clinical use would inhibit the buildup of inclusions stopping the aggregated alpha synuclein protein which would slow the progression of the disease. To read more, click here.
Microsurgical Approaches to Aneurysms and Skull Base Diseases 2017
Oct. 26-28, 2017; Jacksonville, Fla.
Pituitary Tumors: Diagnostic and Treatment Dilemmas
Oct. 27, 2017; New York
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
8th World Congress of Neuroendoscopy
Nov. 1-4, 2017; Cape Town, South Africa
3rd Annual Selected Topics in Craniomaxillofacial Surgery
Nov. 4, 2017 - Nov. 5, 2017; Boston, Mass.